Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections

International Journal of Clinical Practice

Volumn 54, Issue 8, 2000, Pages 497-503

  Parish, L C ^a   Routh, H B ^a   Fidelholtz, J ^a   Werscheer', P ^a   Averstock, D H ^a   Church, D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; MOXIFLOXACIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; CEPHALEXIN; CEPHALOSPORINS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STREPTOCOCCAL INFECTIONS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0033746529     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. File TM. Tan JS. Treatment of skin and soft-tissue infections. Am J Surg 1995; 169(suppl SA): 27S-33S.
2. Parish LC. Witkowski JA. Systemic management of cutaneous bacterial infections. Am J Meet 1991: 91(suppl 6a): 106S-110S.
3. Parish LC. Witkowski JA. Cephalosporin therapy in dermatological practice. Clin Dermatol 1992: 9: 459-469.
4. Phillips G. Paraît D. Orange GV el ai. Erythromycin-resistant Streptococcus pyogenes. J Antimicrob Chemother 1990: 2:5: 723-724.
5. Siefert HM. Domdey-Bette A.Hennnger K et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other animals. J Antimicrob Chemother 1999; 43(suppl B): 69-77.
6. Stass HH. Dalhoff A, Kubitza D el al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8methoxyquinolone administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-2065.
7. Malathum K. Singh KV. Murray BE. In vitro activity of moxifloxacin. a new 8-methoxyquinolone, against Gram positive bacteria. Diagn Microbiol Infect Dis 1999:35: 127-133.
8. Jones ME, Visser MR. Klootwijk M et al. Comparative activity of clinafloxacin. grepafloxacin, levofloxacin. moxifloxacin. ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linizolid, quinupristindalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin resistant and susceptible Staphvlococcus aureus strains. Antimicrob Agents Chemother 1999; 43: 421-423.
9. Esposito S. Noviello S, lanniello F. //; vitro activity of moxitloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of Group A Beta-hacmolytic Streptococcus (GABHS). Chemotherapy 2000; 46( 1 ): 23-27.
10. SantanamP, Huf E, KayserFH. Activity of Bay 12-8039 (Moxifloxacin) and further fluoroquinolones against speciated Staphylococci and potential of Staphylococci to develop resistance. Abstr. E-197. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. San Diego.California, 1998.
11. Goldstein EJ. Citron DM, Hudspeth M et al. In vitro activity of Bay 128039. a new 8-methoxyquinolone. compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother 1997; 41(7): 1552-1557.
12. Performance Standard for Antimicrobial Disk Susceptibility Tests 5th edn. Approved Standard. M2-A5. Villanova. Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
13. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 3rd edn. Approved Standard. M"'-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards. 1993.
14. Siefert HM. Kohlsdorfcr C. Steinke W et al. Pharmacokinetics of the 8-methoxyquinolone moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 1999; 43(suppl B): 61-67.
15. Wise R. Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. J Antimicrob Chemother 1999; 43: 1508-1510.
16. Stass H. Brunner M, Eichler HG et al. Comparison of skin Blister Fluid and interstitial tissue kinetics of Bay 12-8039 in healthy volunteers using microdialysis. Abstr. A-12. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. San Diego.California. 1998.
17. Cockburn J. Gibberd RW. Reid AL et al. Determinants on non-compliance with short-term antibiotic regimens. BMJ 1987; 295: 814-818.
18. Gentry LO. Therapy with newer oral B-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin Infect Dis 1992: 14: 285-297.
19. Dalhoff A. Lack of in vivo emergence of resistance against Bay 12-8039 in S. aureus and S. pneumoniae. In: R. Finch & D. Adam. eds. Moxifloxacin in Practice. Vol. 1. Oxford, UK: Maxim Medical 1999, 81-91.
20. Durham EJ. Amycs GB. Dalhoff A et al. Mechanism of activity of moxi floxacin against Staphvlococcus aureus in vitro. In: R. Finch & D. Adam, eds. Mo\iflo\acin in Practice. Vol. I. Oxford. UK: Maxim Medical 1999,57-62.